Circulating LIPCAR is a potential biomarker of heart failure in patients post-acute myocardial infarction

Area of Science:

• Biochemistry
• Cardiology
• Molecular Biology

Background:

• Reduced ejection fraction heart failure (HF) is linked to elevated LIPCAR, a long noncoding RNA associated with adverse cardiac remodeling and prognosis.
• Identifying early biomarkers for HF post-acute myocardial infarction (AMI) is crucial for timely intervention.

Purpose of the Study:

• To investigate the role of LIPCAR as a potential biomarker for early detection of HF in patients following AMI.
• To assess the diagnostic value of LIPCAR levels in differentiating HF patients post-AMI from those without HF.

Main Methods:

• A cohort study involving 127 patients with AMI was conducted.
• Patients were categorized into two groups: 59 with HF post-AMI and 68 without HF post-AMI.
• LIPCAR levels were measured, and receiver operating characteristic (ROC) curves were used to evaluate diagnostic accuracy (AUC).

Main Results:

• LIPCAR levels were significantly higher in patients with HF post-AMI compared to patients without HF post-AMI.
• LIPCAR demonstrated a high predictive value for the diagnosis of HF post-AMI, with an Area Under the Curve (AUC) of 0.985.
• These findings suggest LIPCAR's strong association with the presence of HF after AMI.

Conclusions:

• LIPCAR may serve as a valuable and sensitive biomarker for the early diagnosis of heart failure in the context of acute myocardial infarction.
• Further research can explore the therapeutic implications and mechanistic roles of LIPCAR in HF development post-AMI.